Zevra Therapeutics Inc [ZVRA] stock is trading at $9.23, down -1.81%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The ZVRA shares have gain 1.54% over the last week, with a monthly amount drifted -21.65%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zevra Therapeutics Inc [NASDAQ: ZVRA] stock has seen the most recent analyst activity on July 02, 2025, when H.C. Wainwright initiated its Buy rating and assigned the stock a price target of $26. On October 07, 2024, Guggenheim initiated with a Buy rating and assigned a price target of $20 on the stock. Maxim Group reiterated its Buy rating and increased its price target to $25 on September 24, 2024. JMP Securities initiated its recommendation with a Mkt Outperform and recommended $17 as its price target on September 24, 2024. Maxim Group reiterated a Buy rating for this stock on April 02, 2024, and upped its price target to $18. In a note dated March 12, 2024, William Blair initiated an Outperform rating.
Zevra Therapeutics Inc [ZVRA] stock has fluctuated between $6.19 and $13.16 over the past year. Currently, Wall Street analysts expect the stock to reach $24 within the next 12 months. Zevra Therapeutics Inc [NASDAQ: ZVRA] shares were valued at $9.23 at the most recent close of the market. An investor can expect a potential return of 160.02% based on the average ZVRA price forecast.
Analyzing the ZVRA fundamentals
Zevra Therapeutics Inc [NASDAQ:ZVRA] reported sales of 84.39M for the trailing twelve months, which represents a growth of 605.36%. Gross Profit Margin for this corporation currently stands at 0.72% with Operating Profit Margin at -1.92%, Pretax Profit Margin comes in at 0.34%, and Net Profit Margin reading is 0.04%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is 0.04 and Total Capital is -0.52. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.53.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.09 points at the first support level, and at 8.94 for the second support level. However, for the 1st resistance point, the stock is sitting at 9.49, and for the 2nd resistance point, it is at 9.74.
Ratios To Look Out For
For context, Zevra Therapeutics Inc’s Current Ratio is 8.62. As well, the Quick Ratio is 8.57, while the Cash Ratio is 1.65. Considering the valuation of this stock, the price to sales ratio is 6.16, the price to book ratio is 3.90 and price to earnings (TTM) ratio is 14.63.
Transactions by insiders
Recent insider trading involved McFarlane Neil F., President and CEO, that happened on Oct 10 ’25 when 19500.0 shares were sold. Director, NEIL F MCFARLANE completed a deal on Oct 10 ’25 to buy 19500.0 shares. Meanwhile, Director FAVORITO TAMARA A bought 3175.0 shares on Sep 12 ’25.
